Edition:
United States

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

64.78USD
14 Dec 2017
Change (% chg)

$0.06 (+0.09%)
Prev Close
$64.72
Open
$64.91
Day's High
$65.61
Day's Low
$64.75
Volume
855,841
Avg. Vol
684,758
52-wk High
$66.18
52-wk Low
$43.81

Chart for

About

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled... (more)

Overall

Beta: 0.71
Market Cap(Mil.): $35,261.52
Shares Outstanding(Mil.): 544.83
Dividend: 0.16
Yield (%): 0.99

Financials

  Industry Sector
P/E (TTM): -- 57.04 15.47
EPS (TTM): -- -- --
ROI: -- 13.33 33.71
ROE: -- 19.92 16.38

Baxter expects $70 million hit to fourth-quarter sales from Hurricane Maria

U.S. hospital products maker Baxter International Inc on Wednesday forecast a nearly $70 million hit to its fourth-quarter revenue, due to manufacturing disruptions arising from Hurricane Maria.

Oct 25 2017

UPDATE 2-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria

* Shares slightly lower (Adds share price, CEO comments from analyst call)

Oct 25 2017

Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria

Oct 25 Hospital products maker Baxter International Inc on Wednesday forecast a nearly $70 million hit to its fourth-quarter revenue due to manufacturing disruptions arising from Hurricane Maria.

Oct 25 2017

BRIEF-Baxter provides update on Puerto Rico recovery status post Hurricane Maria

* Baxter provides update on Puerto Rico recovery status post Hurricane Maria

Oct 12 2017

BRIEF-Baxter International Inc - ‍launches DeviceVue Advanced Asset Tracking System for Sigma Spectrum Infusion System​

* Baxter International Inc - ‍launches DeviceVue Advanced Asset Tracking System for Sigma Spectrum Infusion System​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Sep 27 2017

BRIEF-Baxter International ‍announces commercial launch of new indication for oXiris set​

* Baxter launches first 3-in-1 set for use in continuous renal replacement therapy and sepsis management protocols

Sep 26 2017

BRIEF-Baxter and MATTER Healthcare on patient-driven innovation

* Baxter and MATTER Healthcare Incubator Partner on patient-driven innovation

Aug 31 2017

Big-name U.S. hedge funds shed healthcare stocks during the rally in second-quarter

NEW YORK Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.

Aug 14 2017

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

Jul 20 2017

U.S. FTC approves Baxter's acquisition of Claris business with condition

WASHINGTON, July 20 Baxter International Inc and Claris Lifesciences Ltd have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.

Jul 20 2017

Earnings vs. Estimates